British Journal of Cancer · 2001 · 59 citations · 28 references
MedicineOncologyPathologyCancer GeneticsChemotherapyMolecular OncologyCancer Genomic InstabilityChemotherapy ResistanceMalignant NeoplasmsOvarian CancerOvarian NeoplasiaTumor MarkersImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingMicrosatellite Instability AnalysisMicrosatellite Instability In Ovarian CancerMicrosatellite TypingOvarian Cancer Chemotherapy
To clarify the mechanism of acquired CDDP resistance in ovarian cancer, we compared the microsatellite instability (MSI) by the amplification of 10 microsatellite loci and immunohistochemical detection of hMSH2 and hMLH1 expression between the primary resected tumours and the secondary resected residual tumours after 5 or 6 courses of CDDP-based chemotherapy in the 24 cases of ovarian cancer. Of the 24 primary resected tumours, 9 (37.5%) showed MSI (7 cases of MSI-L, 2 cases of MSI-H), while 15 (72.5%) were microsatellite stable tumours (MSS). The primary tumours also had MSI in the residual tumours after CDDP-based chemotherapy. However, all of the cases with MSS in the primary resected tumours exhibited MSI (2 cases were MSI-L, and 13 cases were MSI-H) in the residual tumours after CDDP-based chemotherapy (P< 0.001). Furthermore, 11 (73.3%) of these cases which changed from MSS to MSI also had a change in the expression of hMLH1 from positive to undetectable (P< 0.001). Our data suggest that tumour MSI changes during CDDP-based chemotherapy, and that the loss of hMLH1 expression is one of the factors that has the greatest effect on this transformation.
28
C. Richard Boland, Stephen N. Thibodeau, Stanley R. Hamilton et al. · PubMed · 1998 · 4.1K citations
Life Sciences, Genetics, Oncology +17
WHO Handbook for Reporting Results of Cancer Treatment
M K Palmer · British Journal of Cancer · 1982 · 2.2K citations · Full text
Medicine, Oncology, Cancer Control +11
WHO handbook for reporting results of cancer treatment
Richard Sylvester · Controlled Clinical Trials · 1980 · 1.1K citations
Medicine, Oncology, Cancer Control +11
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
Fred Bunz, Paul M. Hwang, Chris Torrance et al. · Journal of Clinical Investigation · 1999 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +17